deliv solid result better top-and-bottom line
result mostli driven favor fx said context organ
growth beat sever life scienc tool brethren consist core trend
organ growth around still screen lag peer rel basi
revenu million grew came expect
said fx drove beat vs model coupl stronger
 contribut expect euroimmun ep came
better forecast lower expect tax rate ad
beat
organ growth around similar forecast manag
tout pro-forma organ growth aid recent euroimmun
acquisit reassur see acquisit contribut nice growth
though critic drive acceler growth base
busi order achiev long-term ambit growth ambit
diagnost busi rev appear pois better growth lag
product asset larger discoveri analyt system segment rev
drive compar growth peer context view long-
term target optimist compani guid hsd long-term organ
revenu growth op margin
remain cautiou valuat line life scienc tool peer
reiter underweight rate
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
underweight compel
portfolio nich product across environment
human health long-term outlook
organ growth margin improv
compel believ share
range-bound near term get better
visibl emerg market revenu
opportun china nucleic acid test
newborn screen drive upsid
ebitda forecast upsid ebitda
million yield upsid case
emerg market fx remain pressur drive
downsid estim
downsid ebitda million yield downsid
case
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
deliv solid result better top-and-bottom line result
mostli driven favor fx said context organ growth beat
sever life scienc tool brethren consist core trend organ growth
around still screen lag peer rel basi revenu million
grew came expect said fx drove beat
vs model coupl stronger contribut expect
euroimmun ep came better forecast
lower expect tax rate ad beat
organ growth around similar forecast manag tout
pro-forma organ growth aid recent euroimmun acquisit
reassur see acquisit contribut nice growth though critic
drive acceler growth base busi order achiev
long-term ambit growth ambit diagnost busi rev
appear pois better growth lag product asset larger discoveri
analyt system segment rev drive compar growth peer
context view long-term target optimist compani
guid hsd long-term organ revenu growth op margin
remain cautiou valuat line life
scienc tool peer reiter underweight rate
result rais revenu ep expect larg
reflect favor fx expect lower tax rate well
higher outlook euroimmun full-year revenu expect billion
million midpoint previou guidanc repres increas y/i
revenu guidanc assum million million previous tailwind
fx million contribut million euroimmun
euroimmun acquisit expect provid tailwind around
impli guid organ growth geograph
compani anticip msd organ growth america europ along hsd
growth asia organ growth guidanc assum organ growth diagnost
da despit declin adjust oper margin
compani continu expect expans addit
assum tax rate prior expect
dilut share count million compani anticip tax rate would
repres increas y/i better origin expect due favor
outcom treasuri depart guidanc tax reform
rais ep guidanc rais attribut
beat quarter due slightli higher organ growth expect
reduct tax rate guidanc compani expect revenu
million repres organ growth contribut euroimmun
tailwind fx ep anticip materi impact
revenu improv y/i million emb underli
organ growth roughli tailwind euroimmun acquisit
tailwind fx revenu came ahead expect guidanc due better
organ growth favor fx stronger contribut euroimmun
quarter organ growth result diagnost segment came
expect versu model da outperform versu
drove modest organ growth upsid compani post organ growth
end market geographi except industri end market
declin due time relat issu remain optimist around
cadenc new product launch cite new product contribut million
revenu
guidanc guidanc y/i ebit barclay inc
revenu organ growth
revenu growth solid compani busi segment
diagnost segment revenu revenu grew organ
euroimmun organ period growth driven infecti diseas
along solid result reproduct health particularli haoyuan tulip
euroimmun acquisit ad million revenu growth across
diseas state describ observ four close
acquisit euroimmun decemb expand compani presenc
autoimmun allergi diagnost model organ growth
diagnost
food msd growth
discoveri analyt solut revenu revenu grew
organ quarter embed growth rate quarter msd
environment hsd growth biopharma industri end market declin
lsd quarter mainli result weaker chemic demand strength
biopharma continu benefit strong result compani onesourc
busi perform well quarter model organ growth
da
academ govern msd growth
euroimmun acquisit appear good start post growth teen
revenu million quarter manag rais full-year outlook
revenu though improv forecast fx
driven remind complet major acquisit euroimmun
decemb euroimmun global manufactur diagnost workflow
focu autoimmun test grow presenc infecti diseas allergi
test euroimmun acquisit push mix faster grow market
addit top-lin growth one critiqu perkinelm
thesi compani structur lower growth profil peer given
lack biopharma product asset meaning industri presenc take
advantag recent improv end market euroimmun gener around
million revenu increas compound-annual-growth-rate past year
manag note expect growth low-to-mid teen look forward
compani doesnt want necessarili constrain level growth
combin expand reach autoimmun allergi diagnost market
offer new infecti diseas capabl custom china earli integr
us gone well number placement larg refer lab well
anticip fda approv new assay year overal euroimmun growth
broad-bas geograph term test area effort increas
manufactur china euroimmun close open larg facil tianjin
assum recent growth rate hold euroimmun could add pro-
forma top-lin growth
birth rate global headwind newborn screen
busi higher test util drove msd growth quarter
approxim global market share newborn screen first trimest prenat risk
assess strong brand broad global channel compani expect
high-singl digit growth newborn screen driven three factor
birth rate penetr screen number test perform per babi
market outsid us western europ repres signific
opportun recent strength busi driven menu expans
china enabl new mass spectrometri technolog allow
test per sampl overal screen penetr roughli china averag
util test per newborn util ms techniqu lower roughli
compani also see immens opportun india babi
screen shown chart approxim million birth
year global perkinelm estim new babi screen market
test perform per child
leader newborn screen particularli sensit chang
global birth rate follow broad decreas birth appear trend
revers cdc report increas addit
birth declin europ though increas china due end
one-child polici remind perkinelm earn call compani note
newborn screen busi slightli quarter
entir surpris given recent commentari slow birth rate still
compani state past quarter newborn screen busi
remain strong due menu expans penetr screen util
per babi remain low emerg market countri util per babi
roughli test compani note consid number
test screen notabl effect birth rate would repres risk
compani
millionsnorth americawestern europechinarest worldtotalnumb per barclay inc
y/i growth birth rate region
proxi birth rate note deliveri weak declin
similar result sinc stack growth
mute way track newborn screen trend track hca
quarterli commentari deliveri compar annual birth rate
report lag hca commentari give us real-tim view market trend
biopharma increas hsd quarter driven sustain strength
onesourc look forward continu favor exposur peer greater
biopharma product exposur biopharma busi
revenu grew organ onesourc compani servic offer continu
key growth driver onesourc lab servic offer continu benefit
outsourc trend biopharma major area focu growth
also call biopharma product area strength quarter
compani biopharma tool predominantli use discoveri front end
research activ biopharma sponsor unlik peer lack major
presenc liquid chromatographi led lower rel growth rate within
biopharma mix compani
biopharma said given weaker margin profil faster growth busi
pressur margin da segment
note alloc servic revenu research/product total
end market commentari solid quarter except
industri end market end market geographi grew organ biopharma
grew high-singl digit driven broad strength across compani
product servic onesourc busi diagnost end market post
organ growth led infecti diseas grew mid-teen food
end market continu strong compani grow mid-singl digit
quarter environment end market deceler mid-singl digit growth low-
doubl digit growth industri end market declin y/i
manag attribut softer result time issu lastli academ
govern end market increas mid-singl digit
geograph compani report high-singl digit organ growth asia mid-
singl digit growth america europ bric region broadli post
strong growth high-teen compani see recoveri brazil realiz
continu strength china mid-teen addit note result
india strong quarter look continu expand reach
india recent tulip diagnost acquisit compani enthusiast
leverag tulip platform introduc legaci euroimmun product
market
perkinelm geograph divers rev
perkinelm revenu breakdown end market
gross margin prior year period adjust
fx compani note gross margin would expand fx neutral
basi outsid fx gross margin aid acquisit euroimmun
product improv neg impact unfavor mix perkinelm
expect gross margin improv
perkinelm gross margin ebitda margin
sg ex-stock comp expens increas y/i repres
revenu sg increas primarili driven increment expens form
euroimmun acquisit expens total sale y/i
increas invest vanadi well impact euroimmun
compani also focus new product initi contribut million
expect gener total million revenu
perkinelm adjust sg trend
report adjust ebit margin y/i
margin neg impact acquisit euroimmun trend
season weak first quarter also fx headwind rel compani
expect quarter margin improv da segment y/i
margin diagnost busi sever impact season
euroimmun y/i compani anticip margin improv
y/i addit continu target oper margin
perkinelm ebit margin annual growth
non-gaap ep increas y/i estim ep
beat driven higher expect organ growth lower anticip tax
non-gaap ep growth
cffo million quarter capital-expenditure million repres
revenu million quarter million
expect compani repurchas million share quarter follow
divestitur medic imag busi subsequ tulip euroimmun
acquisit cash balanc million
perkinelm use oper million
capital-expenditure mm except ep reportedincom growth profit ebitda ebit debt pre-tax pre-tax tax net net researchprior yearprior quarter barclay inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
